ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We showed that JNJ-165 significantly and synergistically increased TKIs oncotoxicity both in CML cell lines with p53 mutant and primary CML cells with BCR/ABL-positive, while the combination was not significant toxic for MNCs from BCR/ABL-negative CML patient.